UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

CURRENT REPORT

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

 

Date of Report (Date of Earliest Event Reported): July 29, 2013

 

Cal-Maine Foods, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 000-04892 64-0500378

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

3320 Woodrow Wilson Avenue

Jackson, MS 39207

(Address of principal executive offices (zip code))

 

601-948-6813

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 2.02.   Results of Operations and Financial Condition

 

On July 29, 2013, Cal-Maine Foods, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal 2013 fourth quarter and year ended June 1, 2013. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report.

 

Item 9.01.   Financial Statements and Exhibits

 

(d)Exhibits

 

99.1Press Release issued by the Company on July 29, 2013

 

SIGNATURES

 

Pursuant to the requirements for the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CAL-MAINE FOODS, INC.
     
Date: July 29, 2013 By:    /s/ Adolphus B.  Baker
 

Adolphus B. Baker

Chairman, President and Chief Executive Officer

  

2